Impact of tumor suppressor gene co-mutations on differential response to EGFR TKI therapy in EGFR L858R and Exon 19 deletion lung cancer

JA Hellyer, MN White, RM Gardner, K Cunanan… - Clinical Lung Cancer, 2022 - Elsevier
Background In most studies, patients with EGFR L858R mutant non-small cell lung cancer
(NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy …
被引用次数：17 相关文章

Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer

JA Hellyer, MN White, RM Gardner… - Clinical lung …, 2022 - pubmed.ncbi.nlm.nih.gov
Background In most studies, patients with EGFR L858R mutant non-small cell lung cancer
(NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy …

Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.

JA Hellyer, MN White, RM Gardner, K Cunanan… - Clinical Lung …, 2021 - europepmc.org
Background In most studies, patients with EGFR L858R mutant non-small cell lung cancer
(NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy …

Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer

JA Hellyer, MN White, RM Gardner… - Clinical Lung …, 2022 - clinical-lung-cancer.com
Background In most studies, patients with EGFR L858R mutant non-small cell lung cancer
(NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy …

Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer

JA Hellyer, MN White, RM Gardner… - Clinical Lung …, 2022 - clinical-lung-cancer.com
Background In most studies, patients with EGFR L858R mutant non-small cell lung cancer
(NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy …